Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta Group SA : Technically solid

11/22/2021 | 03:07am EST
long trade
Stop-loss triggered
Entry price : 145CHF | Target : 179CHF | Stop-loss : 131CHF | Potential : 23.45%
Shares in Medacta Group SA do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the CHF 179.
Medacta Group SA : Medacta Group SA : Technically solid
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.31 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 365 M 414 M 414 M
Net income 2021 58,2 M 65,9 M 65,9 M
Net Debt 2021 75,6 M 85,6 M 85,6 M
P/E ratio 2021 38,9x
Yield 2021 0,66%
Capitalization 2 228 M 2 434 M 2 523 M
EV / Sales 2021 6,31x
EV / Sales 2022 5,53x
Nbr of Employees 1 246
Free-Float -
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 111,40 €
Average target price 132,07 €
Spread / Average Target 18,6%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-15.49%2 630
ABBOTT LABORATORIES-10.59%215 794
MEDTRONIC PLC2.08%141 985
BECTON, DICKINSON AND COMPANY5.23%75 431
HOYA CORPORATION-11.34%49 186
BAXTER INTERNATIONAL INC.0.51%43 200